If you think your current antidepressant isn’t helping, it probably isn’t.

Major Depression (MDD) is one of the most common conditions on the planet. Approximately 17.3 million adults across America suffer a depressive episode during any given year. Worldwide, it affects 300 million people.

In some people, antidepressant SSRIs and SNRIs effectively resolve MDD symptoms. However, these medications do not work for everyone—especially since symptoms can vary from person to person—from loss of interest in once pleasurable things to insomnia and fatigue. Thus, there continues to be an unmet need for new drug therapies.

But you can do something. Right now, experts are evaluating investigational MDD medications. For yourself, for those you love, and for future generations, please consider volunteering for clinical trials. Join the fight against MDD. Together, we could help change lives.

Take the next step to see if you qualify for local research studies for people with Depression. But don’t delay — space is limited!

Get started now

How does it work?

1

Tell us a little bit about yourself

2

Answer some questions about your health

3

We will connect you to available studies in your area

Just takes a few minutes

Get started now

COVID-19 update — we remain open.

For the safety of both staff and patients, we require that our research sites are COVID-19 SMART facilities. That means they use best practices to reduce virus exposure and are dedicated to ensuring they remain open and available for the research of investigational medications.

COVID-19 SMART steps we are taking to ensure safety include:

  • Greatly increased availability of video office visits
  • Ensuring social distancing measures are taken in all waiting areas
  • Continuing the practice of cleaning and disinfecting exams rooms thoroughly between every patient visit
  • Appropriate personal protective equipment (PPE) for all staff members at our health clinics

AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.